Abstract
Fifty-five depressed menopausal patients took part in a randomized double-blind cross-over trial using `Harmogen' (piperazine oestrone sulphate) and placebo. The Beck depression inventory, hot flush counts, and patients' subjective assessment of well-being were used to assess clinical status. Hormonal, biochemical and coagulation profiles were carried out. Hot flushes improved significantly on oestrogen compared with placebo. Depression scores and well-being showed significant and equal improvement on oestrogen and placebo. Significant improvement in flushes in patients on placebo was observed in the first half of the trial but did not occur in the second half, in patients who had previously taken oestrogen. No significant changes occurred in biochemistry. Coagulation tests showed acceleration of the prothrombin time in patients taking `Harmogen' compared with those on placebo. Piperazine oestrone sulphate is a relatively weak but safe oestrogen preparation, effective in treatment of vasomotor symptoms but no more effective than placebo in the treatment of depression.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Antunes C. M., Strolley P. D., Rosenshein N. B., Davies J. L., Tonascia J. A., Brown C., Burnett L., Rutledge A., Pokempner M., Garcia R. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med. 1979 Jan 4;300(1):9–13. doi: 10.1056/NEJM197901043000103. [DOI] [PubMed] [Google Scholar]
- BECK A. T., WARD C. H., MENDELSON M., MOCK J., ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
- Ballinger C. B. Psychiatric morbidity and the menopause; screening of general population sample. Br Med J. 1975 Aug 9;3(5979):344–346. doi: 10.1136/bmj.3.5979.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Coope J., Thomson J. M., Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J. 1975 Oct 18;4(5989):139–143. doi: 10.1136/bmj.4.5989.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson D. A., Heather B. B. The sensitivity of the Beck depression inventory to changes of symptomatology. Br J Psychiatry. 1974 Aug;125(0):184–185. doi: 10.1192/bjp.125.2.184. [DOI] [PubMed] [Google Scholar]
- Letter: Oestrogens as a cause of endometrial carcinoma. Br Med J. 1976 May 8;1(6018):1144–1145. doi: 10.1136/bmj.1.6018.1144-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McKay Hart D., Lindsay R., Purdie D. Vascular complications of long-term oestrogen therapy. Front Horm Res. 1977;5:174–191. doi: 10.1159/000401993. [DOI] [PubMed] [Google Scholar]
- Poller L., Thomson J. M., Coope J. A double-blind cross-over study of piperazine oestrone sulphate and placebo with coagulation studies. Br J Obstet Gynaecol. 1980 Aug;87(8):718–725. doi: 10.1111/j.1471-0528.1980.tb04606.x. [DOI] [PubMed] [Google Scholar]
- Smith D. C., Prentice R., Thompson D. J., Herrmann W. L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975 Dec 4;293(23):1164–1167. doi: 10.1056/NEJM197512042932302. [DOI] [PubMed] [Google Scholar]
- Thom M. H., White P. J., Williams R. M., Sturdee D. W., Paterson M. E., Wade-Evans T., Studd J. W. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet. 1979 Sep 1;2(8140):455–457. doi: 10.1016/s0140-6736(79)91504-6. [DOI] [PubMed] [Google Scholar]
- Utian W. H. The true clincal features of postmenopause and oöphorectomy, and their response to oestrogen therapy. S Afr Med J. 1972 Jun 3;46(23):732–737. [PubMed] [Google Scholar]
- Weiss N. S., Szekely D. R., Austin D. F. Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976 Jun 3;294(23):1259–1262. doi: 10.1056/NEJM197606032942303. [DOI] [PubMed] [Google Scholar]